Voya Investment Management LLC Trims Stake in Arcellx, Inc. (NASDAQ:ACLX)

Voya Investment Management LLC lowered its position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 136,203 shares of the company's stock after selling 10,445 shares during the period. Voya Investment Management LLC owned about 0.25% of Arcellx worth $10,445,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ACLX. Headlands Technologies LLC bought a new stake in Arcellx in the 4th quarter worth approximately $41,000. KBC Group NV lifted its holdings in shares of Arcellx by 37.3% in the 4th quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after acquiring an additional 377 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Arcellx in the 4th quarter worth approximately $184,000. Kazazian Asset Management LLC purchased a new stake in shares of Arcellx in the 4th quarter valued at $204,000. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Arcellx during the 4th quarter valued at $214,000. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Arcellx news, insider Rami Elghandour sold 38,300 shares of the stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the completion of the sale, the insider now owns 149,186 shares of the company's stock, valued at $9,252,515.72. This represents a 20.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christopher Heery sold 10,155 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $63.79, for a total transaction of $647,787.45. Following the completion of the transaction, the insider now owns 37,486 shares in the company, valued at $2,391,231.94. The trade was a 21.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,955 shares of company stock valued at $3,504,758. 6.24% of the stock is currently owned by company insiders.

Arcellx Price Performance

Arcellx stock traded up $0.02 during mid-day trading on Friday, hitting $65.55. The company's stock had a trading volume of 305,387 shares, compared to its average volume of 554,266. The business has a 50 day moving average price of $64.90 and a 200-day moving average price of $73.77. Arcellx, Inc. has a 12 month low of $47.88 and a 12 month high of $107.37. The stock has a market cap of $3.61 billion, a price-to-earnings ratio of -92.32 and a beta of 0.33.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The company had revenue of $15.27 million during the quarter, compared to the consensus estimate of $27.42 million. On average, equities research analysts expect that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).